Education
About Us
Working with TipRanks
Follow Us
ISRA - AI Analysis
Top Page
VanEck Israel ETF (ISRA)
Rating:69Neutral
Price Target:
$60.00
Positive Factors
Strong Top Holdings
Several of the largest positions, such as Phoenix and Elbit Systems, have delivered strong year-to-date performance, boosting the ETF’s returns.
Sector Diversification
The ETF is spread across multiple sectors, including technology, financials, and health care, reducing reliance on any single industry.
Healthy Year-to-Date Performance
The fund has shown solid year-to-date growth, indicating strong overall momentum.
Negative Factors
High Geographic Concentration
The ETF is heavily focused on the USA and Israel, limiting exposure to other global markets.
Underperforming Holdings
Some key holdings, such as Teva Pharmaceutical and NICE, have struggled with negative year-to-date performance, which could weigh on future returns.
Moderate Expense Ratio
The ETF’s expense ratio is higher than some low-cost alternatives, which could reduce net returns over time.
ISRA vs. SPDR S&P 500 ETF (SPY)
AUM111.48M
RegionMiddle East & Africa
Expense Ratio0.59%
Beta0.87
IssuerVanEck
Inception DateJun 25, 2013
Dividend Yield0.95%
Asset ClassEquity
Index TrackedBlueStar Israel Global Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,462
30 Day Avg. Volume10,046
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering81
ISRA Summary
The VanEck Israel ETF (ticker: ISRA) is a fund that lets investors tap into Israel’s diverse and innovative economy. It follows the BlueStar Israel Global Index, which includes companies across sectors like technology, finance, and healthcare. Some of its top holdings are CyberArk Software, known for cybersecurity solutions, and Teva Pharmaceutical, a global leader in generic drugs. This ETF is a great choice for those looking to diversify their portfolio geographically and invest in a market known for innovation and growth potential. However, new investors should note that the fund’s performance can be affected by fluctuations in the Israeli economy and global market trends.
How much will it cost me?The VanEck Israel ETF (ISRA) has an expense ratio of 0.59%, which means you’ll pay $5.90 per year for every $1,000 invested. This is slightly higher than average because the fund is focused on a specific niche market (Israeli securities) and requires more active management compared to broad, passively managed index funds.
What would affect this ETF?The VanEck Israel ETF (ISRA) could benefit from Israel's strong reputation in technology and innovation, particularly in cybersecurity, biotechnology, and clean energy, which are key drivers of growth. However, potential risks include geopolitical tensions in the Middle East and global economic slowdowns, which could negatively impact the financial and industrial sectors that make up a significant portion of the ETF's holdings.
ISRA Top 10 Holdings
The VanEck Israel ETF (ISRA) is heavily tilted toward technology and financials, which together make up nearly 70% of its portfolio. Leading the charge is Leumi and Poalim, two financial powerhouses that have been steady performers, benefiting from strong revenue growth and attractive dividends. CyberArk Software is also rising, driven by its shift to subscription models, though profitability concerns linger. On the other hand, Check Point has been lagging, with bearish technical signals offsetting its otherwise solid fundamentals. Meanwhile, Teva Pharmaceutical’s mixed performance highlights ongoing struggles with debt and profitability, holding back the fund’s overall momentum.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Leumi | 8.74% | $9.75M | 98.73B | 101.47% | 78 Outperform | |
| CyberArk Software | 8.12% | $9.05M | $26.29B | 88.58% | 63 Neutral | |
| Teva Pharmaceutical | 7.30% | $8.14M | $23.22B | 11.00% | 56 Neutral | |
| Poalim | 6.96% | $7.77M | 87.28B | 95.32% | 80 Outperform | |
| Check Point | 5.69% | $6.34M | $21.21B | 14.77% | 76 Outperform | |
| Elbit Systems | 4.18% | $4.67M | 72.34B | 108.45% | 75 Outperform | |
| Mizrahi Tefahot | 3.11% | $3.47M | 55.16B | 89.88% | 81 Outperform | |
| Discount | 3.11% | $3.46M | 39.92B | 67.80% | 74 Outperform | |
| NICE | 2.58% | $2.87M | $8.38B | -20.50% | 77 Outperform | |
| Phoenix | 2.51% | $2.80M | 31.93B | 209.39% | 77 Outperform |
ISRA Technical Analysis
Positive
―
Price Trends
53.50
Positive
52.07
Positive
48.41
Positive
Market Momentum
0.47
Negative
58.88
Neutral
58.68
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ISRA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 54.62, equal to the 50-day MA of 53.50, and equal to the 200-day MA of 48.41, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 58.88 is Neutral, neither overbought nor oversold. The STOCH value of 58.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ISRA.
ISRA Peer Comparison
Comparison Results
Performance Comparison
ISRA
VanEck Israel ETF
55.36
16.14
41.15%
TOUS
T. Rowe Price International Equity ETF
―
―
―
DDWM
WisdomTree Dynamic Currency Hedged International Equity Fund
―
―
―
APIE
ActivePassive International Equity ETF
―
―
―
QEFA
SPDR MSCI EAFE StrategicFactors ETF
―
―
―
EIS
iShares MSCI Israel ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents